Induction of melasma by 1064-nm Q-switched neodymium: yttrium-aluminum-garnet laser therapy for acquired bilateral nevus of Ota-like macules (Hori nevus): A study on related factors in the Chinese population
Induction of melasma by 1064-nm Q-switched neodymium: yttrium-aluminum-garnet laser therapy for acquired bilateral nevus of Ota-like macules (Hori nevus): A study on related factors in the Chinese population
复制标题
1064 nm调Q钕诱导黄褐斑：钇铝石榴石激光治疗获得性双侧太田样斑痣（堀痣）：中国人群相关因素研究
DOI：
10.1111/1346-8138.13193
复制
发表时间：
2016-06-01
影响因子：
3.1
通讯作者：
Li, Ji
中科院分区：
文献类型：
--
作者：
Wang, Ben;Xie, Hong-fu;Li, Ji
激光治疗已成为获得性双侧太田样斑疹(ABNOM)的常用治疗手段。为了解激光治疗ABNOM前后诱发和加重黄褐斑的比率，并观察激光治疗诱发和加重黄褐斑的相关危险因素，我们采用病例系列和病例对照研究方法，对1268例接受1064 nm调QY3+石榴石激光(QNYL)治疗的成年患者的相关因素进行了分析。总体而言，24.0%的ABNOM患者有混合性黄褐斑。在无黄褐斑的患者中，年龄>35岁的患者激光治疗后黄褐斑的发生率较高(P<；0.0001)，年龄小于10 cm(2)的患者(P=0.027)、颜色较浅(类似黄褐色)的患者(P=0.021)和皮肤类型更接近IV型(P<；0.0001)。新的黄褐斑病变也最常出现在颧区(P<；0.0001)。在有黄褐斑的ABNOM患者中，89.5%的患者经历了黄褐斑的恶化，而与上述相关因素无关。我们的结论是，在ABNOM患者中，尤其是同时患有ABNOM和黄褐斑的患者，在1064 nm QNYL治疗后，诱发黄褐斑的风险很大。ABNOM患者应尽早治疗，年龄在35岁之前。
Laser treatment has emerged as a common treatment modality for acquired bilateral nevus of Ota-like macules (ABNOM). To identify the ratio of melasma induction and exacerbation before and after laser therapy for ABNOM and to observe the risk factors related to the induction and exacerbation of melasma by laser therapy, we analyzed related factors of 1268 adult Chinese patients who underwent 1064-nm Q-switched neodymium:yttrium-aluminum-garnet (Nd:YAG) laser (QNYL) treatment using case series and case-control studies. Overall, 24.0% of the ABNOM patients had mixed melasma. Among the ABNOM patients without melasma, after laser therapy the development of melasma was more frequently noted in patients older than 35 years (P < 0.0001), as well in patients whose ABNOM was less than 10 cm(2) (P = 0.027), ABNOM were light (similar to yellow-brown) in color (P = 0.021) and skin types were closer to type IV (P < 0.0001). New melasma lesions also appeared most frequently in the zygomatic region (P < 0.0001). Among the ABNOM patients with melasma, 89.5% experienced worsening of their melasma, irrespective of their related factors above. We concluded that the risk of inducing melasma is great after 1064-nm QNYL treatment in ABNOM patients, and particularly in the patients with both ABNOM and melasma. ABNOM patients should be treated as early as possible and before the age of 35 years.